Oss/Ghent, Netherlands/Belgium, October 2022 – INDIGO, a consortium of public and
private R&D organisations for development of improved influenza virus vaccines, has started
a Phase 1 trial with a novel, adjuvanted, low-dose seasonal influenza vaccine. Safety,
tolerability, and immunogenicity of TETRALITE, a combination of 1/5th of a dose of a licensed
influenza vaccine and the novel LiteVax Adjuvant, will be investigated in healthy subjects.
In nonclinical studies, TETRALITE generated unprecedently high immune responses without
detectable systemic or local side-effects. This first-in-human trial marks an important
milestone in the collaborative research of the Center for Vaccinology (Ghent), HarmonyCR
(Melle) and LiteVax BV (Oss) towards a better and affordable seasonal influenza vaccine for
LiteVax BV is a biopharmaceutical company focusing on the development of novel vaccine
adjuvants. The versatile adjuvant technology exploited in TETRALITE is based on a synthetic
carbohydrate fatty acid monosulphate ester (www.litevax.com) and investigated with other
The Centre for Vaccinology (CEVAC), Ghent University Hospital and Ghent University, is
dedicated to contributing to the development of effective vaccines for the prevention of
infectious diseases. CEVAC has a clinical trial unit and an immunomonitoring lab with over 25
years of experience in conducting clinical vaccine trials using the highest quality standards
INDIGO is an interdisciplinary consortium consisting of 16 partners from India, EU and US
funded by the European Union Horizon 2020 program and the Department of Biotechnology,
Ministry of Science and Technology, Government of India (grant ID 874653; www.indigovaccines.eu).
For more information on the INDIGO Project, please contact email@example.com.
For more information on the Clinical Trial, please contact firstname.lastname@example.org.
For more information on the LiteVax Adjuvant, please contact email@example.com